Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MRD”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07661173
What this trial is testing

A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Anhui Provincial Cancer Hospital 154
Not applicableStudy completedNCT02010931
What this trial is testing

Retrospective Analysis of Survival in Adult MRD Positive Acute Lymphoblastic Leukemia Patients

Who this might be right for
Acute Lymphoblastic Leukemia
Amgen 310
Testing effectiveness (Phase 2)Ended earlyNCT03523429
What this trial is testing

PETHEMA-BLIN-01/PET069014 (BLIN-01)

Who this might be right for
Philadelphia Chromosome-negative or BCR-ABL-negative, CD19-positive ALL
PETHEMA Foundation 11
Testing effectiveness (Phase 2)UnknownNCT04754035
What this trial is testing

Clinical Study With Ibrutinib and Venetoclax for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Who this might be right for
Chronic Lymphocytic Leukemia
Paolo Ghia 31
Testing effectiveness (Phase 2)Looking for participantsNCT06993675
What this trial is testing

Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)

Who this might be right for
Multiple Myeloma
Noffar Bar 50
Not applicableUnknownNCT03564977
What this trial is testing

CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation

Who this might be right for
Lymphoma, B-CellLeukemia, B-CellMinimal Disease, Residual
Qingdao Central Hospital 20
Not applicableEnded earlyNCT01570465
What this trial is testing

Prospective Study on Severe Infections on Acute Myeloid Leukemia (AML) Patients

Who this might be right for
AMLAdult
Gruppo Italiano Malattie EMatologiche dell'Adulto 144
Not applicableUnknownNCT06081777
What this trial is testing

Significance of MRD Monitoring in Patients With Potentially Resectable Stage III Non-small Cell Lung Cancer

Who this might be right for
NSCLC
Peking University Cancer Hospital & Institute 65
Testing effectiveness (Phase 2)WithdrawnNCT03515707
What this trial is testing

Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaMinimal Residual Disease Negativity
Fred Hutchinson Cancer Center
Testing effectiveness (Phase 2)Looking for participantsNCT06517212
What this trial is testing

Tirzepatide Weight Loss for MRD+ Early Breast Cancer

Who this might be right for
Breast CancerBreast NeoplasmsBreast Cancers
Baylor Research Institute 48
Large-scale testing (Phase 3)UnknownNCT03846362
What this trial is testing

A Prospective Multicenter Clinical Trial of MRD-based Treatment Strategy in Children and Young Adults With AML

Who this might be right for
Acute Myeloid Leukemia, Childhood
Federal Research Institute of Pediatric Hematology, Oncology and Immunology 500
Early research (Phase 1)UnknownNCT04309084
What this trial is testing

Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

Who this might be right for
Multiple MyelomaNeoplasm, Plasma CellNeoplasms by Histologic Type+17 more
Celularity Incorporated 29
Testing effectiveness (Phase 2)Looking for participantsNCT07507318
What this trial is testing

Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission

Who this might be right for
Diffuse Large B-Cell Lymphoma
Rong Tao 69
Early research (Phase 1)UnknownNCT03685786
What this trial is testing

CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT

Who this might be right for
Leukemia, Lymphocytic, Acute, B-CellLeukemia, Lymphocytic, Chronic, B-CellLymphoma, B-Cell
Shenzhen Second People's Hospital 20
Not applicableLooking for participantsNCT06211166
What this trial is testing

Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction

Who this might be right for
Acute LeukemiaMDSMDS/MPN+1 more
Peking University People's Hospital 300
Post-approval studies (Phase 4)Looking for participantsNCT06409702
What this trial is testing

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

Who this might be right for
Newly DiagnosedHigh RiskMRD+1 more
The First Affiliated Hospital of Soochow University 59
Early research (Phase 1)Looking for participantsNCT05192122
What this trial is testing

Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD

Who this might be right for
Multiple Myeloma
University of Illinois at Chicago 50
Not applicableNot Yet RecruitingNCT07132502
What this trial is testing

Treatment Intermittent Periods Based on ctDNA-MRD（Circulating Tumor DNA-minimal Residual Disease） Status in Advanced HER2-Positive Breast Cancer

Who this might be right for
Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 24
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07748689
What this trial is testing

Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.

Who this might be right for
Relapsed / Refractory Multiple Myeloma
Polish Myeloma Consortium 228
Not applicableLooking for participantsNCT07131059
What this trial is testing

MRD-positive AML Clinical Study

Who this might be right for
AML, Adult
Institute of Hematology & Blood Diseases Hospital, China 537
Next Page